Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with or without Lenvatinib in resectable HCC
NCT03867370Phase 2Terminated
- Sponsor
- Shanghai Junshi Biosciences Co., Ltd.
- Start
- Apr 2019
- Primary completion
- Aug 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of toripalimab in hepatocellular carcinoma (HCC) (3 arms), sponsored by Shanghai Junshi Biosciences Co., Ltd. Primary endpoint: Pathological response rate at 2 months. Started Apr 2019; status: terminated.
02
Drugs
toripalimab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03867370.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03867370.